AGM, page-18

It’s clear they haven’t recruited any patients that’s why there’s been no announcements/market updates. Previously they were updating when each cohort filled of either DARRT or CEP. There’s been no further announcements as no further cohorts have been filled. Which is next to zero progress given how small the initial dose escalation cohorts are.

you can’t deduct the trials are going well by their duration. They only stop a trial if there’s a serious safety concern, and NOX66 safety profile is clear. We’re picking up the tab, prestigious hospitals run plenty of safe trials that show a medication doesn’t work. I’m not suggesting NOX66 isn’t working, I’m saying you can’t deduct any efficacy from the trials being ongoing. All you can deduct from the lack of updates is they have recruited any more patients.